Found 6 matching trials
Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) PHASE3 To evaluate the safety, tolerability and efficacy of intravenous administra...
Show More Location
Novartis Investigative Site
Learn More & Join Trial
Efficacy and Safety of Intrathecal OAV101 (AVXS-101) in Pediatric Patients With Type 2 Spinal Muscular Atrophy (SMA) PHASE3 This was a Phase III multi-center, single dose (1.2 x 10\^14 vector genomes...
Show More Location
Connecticut Children's Medical Center
Learn More & Join Trial
Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) (OFELIA) PHASE4 This was a phase IV Open-label, single-arm, single-dose, multicenter study,...
Show More Location
Novartis Investigative Site
Learn More & Join Trial
Single-Dose Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1 PHASE3 Phase 3, open-label, single-arm, single-dose, trial of onasemnogene abeparv...
Show More Location
University Hospital Ghent Neuromuscular reference center
Learn More & Join Trial
Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials PHASE3 This is a global, prospective, multi-center study that is designed to asses...
Show More Status
Active Not Recruiting
Location
Child Hosp Of The Kings Daughters
Learn More & Join Trial
Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally to Participants With SMA Who Discontinued Treatment With Nusinersen or Risdiplam PHASE3 This was a Phase IIIb open-label, single arm, multi-center study to evaluat...
Show More Location
Boston Childrens Hospital
Learn More & Join Trial